The binding of several peptides derived from the Plasmodium falkiparum circumsporozoite protein (CS protein) to the human major histocompatibility complex class II proteins HLA-DR5 and -DRw6 was examined in a competition assay. Fixed antigen-presenting cells (APCs) were incubated with various concentrations of each peptide and suboptimal concentrations of stimulator peptides. The binding of the CS peptides to DR5 or DRw6 proteins was then determined in a proliferation assay using two established DR5 or DRw6-restricted T-cell clones with specificity for the stimulator peptides as responder cells. One offive CS peptides, comprising together about 50% of the CS protein sequence, was found to compete with the binding of the stimulator peptides to DR5 and DRw6. The CS peptide CS-(378-398), binding to DR5 and DRw6, was then shown to be able to induce primary in vitro responses of T cells from donors with DR5 and DRw6 haplotypes. CS-(378-398)-induced T-cell clones responded not only to the homologous peptide but also to the native CS protein in the presence of appropriate APCs. The strategy we have applied is of considerable general interest for the engineering of vaccines against any pathogen, since it greatly facilitates the selection of appropriate T-cell epitopes to be incorporated in the vaccine.
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Although vaccination with attenuated pathogens is the most successful area of applied immunology, some widespread pathogens, such as parasites causing malaria, cannot be generated in sufficient quantities for attenuated vaccine preparation. In these cases, it is necessary to engineer vaccines that are able to induce protective immunity. The engineering of vaccines has been greatly facilitated by recent advances in gene technology and our increased understanding of how T cells recognize antigens and how they collaborate with B cells. While the mechanisms that mediate protective immunity against malaria parasites are not yet entirely clear, it is likely that class II (1) and class I major histocompatibility complex (MHC)-restricted T cells (2, 3) , as well as B cells (4) , are involved. In our previous work, we have identified several regions of the circumsporozoite protein (CS protein) of Plasmodium falciparum as epitopes recognized by human T cells (5, 6) . Since, in general, any given T-cell epitope is only recognized in association with one or a few MHC restriction elements (7, 8) , we wished to know the spectrum of HLA antigens with which each T-cell epitope-containing peptide could associate. Therefore, we developed a competition assay that allows us to examine many different peptides for their capacity to bind to different HLA class II proteins. In a second step we examined a peptide selected by the competition assay for its ability to induce primary T-cell responses and to induce T-cell clones able to respond to the native protein in the presence of appropriate antigen-presenting cells (APCs). In the present study, we used these methods to extend our previous work, which had already suggested that only one of four CS peptides tested is a good candidate for incorporation into a vaccine as a T-cell epitope (5) . The results shown here suggest that the strategy we have used can be applied on a much larger scale for the selection of T-cell epitopes to be incorporated in any vaccine.
MATERIALS AND METHODS
Antigens. Peptides were synthesized by the solid-phase technique (9) . Purity was assessed by HPLC and amino acid analysis. Peptide CS-(378-398) corresponds to residues 378-398 of the CS protein sequence, except that the CS protein cysteine residues 384 and 389 were replaced by alanine residues (5). The peptide CS-(23-43), insoluble in culture medium, was dissolved as a stock solution in 6 M urea. The sequences of the "stimulating" peptides used in the studies reported here are described below: CS4325-341): Glu-Pro-Ser-Asp-Lys-His-Ile-Glu-Gln-Tyr-LeuLys-Lys-Ile-Lys-Asn-Ser.
CS-(378-398): Asp-Ile-Glu-Lys-Lys-Ile-Ala-Lys-Met-Glu-LysAla-Ser-Ser-Val-Phe-Asn-Val-Val-Asn-Ser. pl90-(260-273): Leu-Asp-Asn-Ile-Lys-Asp-Asn-Val-Gly-LysMet-Glu-Asp-Tyr. Recombinant proteins dihydrofolate reductase (DHFR)-CSVI-(His)6 and DHFR-CSlA-(His)6 were expressed and purified as described (10) . Briefly, DNA fragments CSVI and CS1A encoding amino acids 309-364 and 362-408 of the CS protein (11), respectively, were integrated into the unique Bgl II restriction site of plasmid pDHFR-(His)6 (10). The resulting plasmids pDHFR-CSVI-(His)6 and pDHFR-CSlA-(His)6 were subsequently used for expression of protein DHFR-CSVI-(His)6 and DHFR-CSlA-(His)6 in Escherichia coli M15 cells harboring plasmid pDMI.1 (12) . The proteins were extracted with 6 M guanidine hydrochloride/0.1 M NaH2PO4, pH 8.0, from the E. coli cell paste and purified according to Hochuli et al. (10) by immobilized metal ion affinity chromatography. The crude extract was directly loaded onto the metal chelate adsorbent. The column was washed first with extraction buffer and then with 8 M urea/0.1 M NaH2PO4/0.01 M Tris-HCl, at pH 8.0,6.5, and 6.0. Finally, DHFR-CSIV-(His)6 and DHFR-CSlA-(His)6 were eluted with a purity of -70% using urea buffer at pH 4.0.
Purification of CS protein from sporozoites was carried out as described (5) .
Cells. The derivation and characterization of T-cell clones HM.37 and AC.129 have been described elsewhere (6, 13 tTo whom reprint requests should be addressed.
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. were carried out as described (5, 14 (Fig. 1) . Clone HM.37 recognizes peptide 325-341 of the CS protein in association with DR5 molecules (6), whereas clone AC.129 is specific for peptide 260-273 of the P. falciparum blood stage p190 protein (18) and DRw6 molecules (Fig. 1) T-cell clones, respectively. All 27 T-cell clones responded well to CS-(378-398) but not at all to a control peptide, CS-(325-341) (data not shown). The MHC restriction of these clones was assessed by testing the effect of anti-MHC class II antibodies on the proliferative response. All 27 clones were DR restricted, since their response was inhibited by anti-DR antibodies but by neither anti-DP nor by anti-DQ antibodies. The restricting DR allele was determined for each clone by using HLA-DR homozygous EBV-B cells as APCs (Fig. 3) . The 17 clones obtained from donor SD(DR5, -7) were DR5 restricted (4 clones) or DR7 restricted (13 clones), whereas the clones from donor BR(DR4, -w6) were either DR4 restricted (5 clones) or DRw6 restricted (5 clones).
In Vitro Induced Antipeptide T-Cell Clones Recognize the P. falciparum CS Protein. The T-cell clones generated from primary in vitro stimulation were assessed for their ability to recognize the parasite-derived CS protein as well as a recombinant polypeptide containing the 378-398 sequence with the native protein's cysteine residues at positions 384 and 389. As shown in Fig. 4 (8, 19) . Peptide CS-(378-398) competes with peptide CS-(325-341) for interaction with DR5 molecules (Fig. 2) . Conversely, peptide CS-(325-341) should compete with CS-(378-398) for the same restriction molecule. Indeed, this is the case (Fig. 5) (24) .
Binding of peptides to MHC class II molecules is a condition necessary, but not sufficient, for the activation of T-cell clones (25) . In some instances, peptide-MHC complexes do not activate T cells, presumably because of the absence of T cells carrying the appropriate T-cell receptor (25) . However, "holes" in the T-cell repertoire seem to represent a relatively unfrequent event in T-cell recognition (26) . Therefore, in most cases, as exemplified by the present results, peptides binding to MHC class II molecules should also be able to induce T-cell activation.
In the present study, we have been able to establish DR5-and DRw6-restricted T-cell clones specific for the peptide that was previously shown to compete with the binding oftest peptides to DR5 and DRw6 proteins. These clones were established from PBMCs of donors who had not been in contact with P. falciparum. In other experiments, we have been able to establish T-cell clones specific for peptides from P. falciparum p190 (13) and from the CS protein (5, 6) by using the blood of unprimed donors or even cord blood lymphocytes (F.S. et al., unpublished data). Recently, Carbone et al. (27) have been able to induce primary responses of class I MHC-restricted murine T cells to peptides. Most of the clones derived from such cultures were unable to respond to the native protein from which the peptides were derived. In contrast to these findings, most of the human class II MHC-restricted clones that we have derived from peptidestimulated cultures of cells from unprimed donors were able to respond not only to the peptides but also to the native protein in the presence of appropriate APCs. The primary T-cell responses to the peptide we selected by using the competition assay therefore indicate the ability of the peptide to induce memory T cells that can be boosted by subsequent infections with the pathogen. We believe that the strategy used in the present study can be applied on a much larger scale to select T-cell epitopes to be incorporated into vaccines against any human pathogen. Although in this initial study we used only two sets of test cells in the competition assay, the results encourage us to establish a larger panel of test cells, which include enough HLA class II restriction specificities to cover the vast majority of the human population. C An
